WO2010142143A9 - 吡啡尼酮类化合物、其制备方法和应用 - Google Patents

吡啡尼酮类化合物、其制备方法和应用 Download PDF

Info

Publication number
WO2010142143A9
WO2010142143A9 PCT/CN2010/000853 CN2010000853W WO2010142143A9 WO 2010142143 A9 WO2010142143 A9 WO 2010142143A9 CN 2010000853 W CN2010000853 W CN 2010000853W WO 2010142143 A9 WO2010142143 A9 WO 2010142143A9
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
pirfenidone compound
pirfenidone
compound
organ
Prior art date
Application number
PCT/CN2010/000853
Other languages
English (en)
French (fr)
Other versions
WO2010142143A1 (zh
Inventor
朱惠霖
谢雷杰
朱振东
殷建明
张二利
Original Assignee
北京凯得尔森生物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京凯得尔森生物技术有限公司 filed Critical 北京凯得尔森生物技术有限公司
Publication of WO2010142143A1 publication Critical patent/WO2010142143A1/zh
Publication of WO2010142143A9 publication Critical patent/WO2010142143A9/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/CN2010/000853 2009-06-11 2010-06-13 吡啡尼酮类化合物、其制备方法和应用 WO2010142143A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910086890 2009-06-11
CN200910086890.1 2009-06-11

Publications (2)

Publication Number Publication Date
WO2010142143A1 WO2010142143A1 (zh) 2010-12-16
WO2010142143A9 true WO2010142143A9 (zh) 2011-02-03

Family

ID=43308395

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/000853 WO2010142143A1 (zh) 2009-06-11 2010-06-13 吡啡尼酮类化合物、其制备方法和应用

Country Status (2)

Country Link
CN (1) CN101921225B (zh)
WO (1) WO2010142143A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015000830A (es) 2012-07-18 2015-10-26 Sunshine Lake Pharma Co Ltd Derivados heterociclicos nitrogenosos y su aplicacion en farmacos.
ES2663806T3 (es) 2013-12-19 2018-04-17 unshine Lake Pharma Co., Ltd. Derivados heterocíclicos nitrogenados y su aplicación en el tratamiento de la fibrosis tisular
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1846699A (zh) * 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
CA2691379C (en) * 2007-06-20 2015-06-09 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20110313004A1 (en) * 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones

Also Published As

Publication number Publication date
CN101921225A (zh) 2010-12-22
WO2010142143A1 (zh) 2010-12-16
CN101921225B (zh) 2013-04-03

Similar Documents

Publication Publication Date Title
ZA201001015B (en) (Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
WO2013096741A3 (en) Organoids comprising decellularized and repopulated placental vascular scaffold
IL204556A0 (en) (cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
EP2273975B8 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
WO2011060213A3 (en) Preparation of sitagliptin and salts thereof
WO2011042918A3 (en) Improved processes for preparing prasugrel and pharmaceutically acceptable salts thereof
HK1117164A1 (en) Dicyclic azaalkane derivatives, preparing method and pharmaceutical use thereof
IL196697A (en) Use of 4 Hydroxy-Alpha-Phenyl Butyl Nitron or its Derivatives to Prepare a Cure for Sensory-Neural Hearing Loss
EP2481739A4 (en) DIHYDROPTERIDINONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL USE
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2011076212A3 (en) Processes for the manufacture of a pharmaceutically active agent
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
WO2011025932A3 (en) Preparation of sitagliptin and salts thereof
WO2011069076A3 (en) Sustained release donepezil formulations
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
WO2009144551A3 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
WO2011073981A3 (en) Betahistine in compositions and methods for treating somnolence
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts
HK1158632A1 (zh) -氧代烷基- -哌嗪- -酮衍生物﹑其製備方法和治療用途
WO2011067236A3 (de) Raltegravir-polymorphe
WO2008059519A3 (en) A process for the preparation of intermediates of rosuvastatin
WO2010142143A9 (zh) 吡啡尼酮类化合物、其制备方法和应用
WO2012018791A3 (en) Preparation of prasugrel hydrochloride
WO2009080745A3 (de) Perhydrochinoxalin-derivate als analgetika

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10785656

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10785656

Country of ref document: EP

Kind code of ref document: A1